Plus   Neg

Stock Alert: Genetic Technologies Jumps 50%

Shares of Genetic Technologies Ltd. (GENE) shares surged over 50% on Wednesday morning. The molecular diagnostics company said it has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in Australia.

GENE is currently trading at $3.51, up $1.25 or 55.31%, on the Nasdaq.

Genetic Technologies is developing a Polygenic Risk Score test for COVID-19, which may enable an assessment of risk of an individual developing a serious disease should they contract the COVID-19 virus. The test is intended to predict 'disease severity' using a combination of genetic and clinical information.

Genetic Technology expects to make its data pack for the COVID-19 Severity Risk Test available to global labs.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.
Follow RTT